IONS
IONIS PHARMACEUTICALS INC
Overview
Ionis Pharmaceuticals designs RNA-targeted medicines to treat serious diseases. The company markets seven approved medicines for conditions including spinal muscular atrophy, amyotrophic lateral sclerosis, hereditary angioedema, and rare metabolic and neurological disorders, with revenue of $944 million in 2025.
IONIS PHARMACEUTICALS INC is a Healthcare company operating in Biotechnology with a $12.54B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 4, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-2913 Q&A exchanges
- Q4 FY2025Earnings2026-02-2511 Q&A exchanges
- Q3 FY2025Earnings2025-10-2921 Q&A exchanges
- Q2 FY2025Earnings2025-07-3015 Q&A exchanges
- Q1 FY2025Earnings2025-04-3011 Q&A exchanges
- Q4 FY2024Earnings2025-02-1914 Q&A exchanges
- Q3 FY2024Earnings2024-11-0628 Q&A exchanges
- Q2 FY2024Earnings2024-08-0116 Q&A exchanges
- Q1 FY2024Earnings2024-05-0714 Q&A exchanges
- Q4 FY2023Earnings2024-02-2124 Q&A exchanges
- Q3 FY2023Earnings2023-11-0228 Q&A exchanges
- Q2 FY2023Earnings2023-08-0917 Q&A exchanges
- Q1 FY2023Earnings2023-05-0324 Q&A exchanges
- Q4 FY2022Earnings2023-02-2220 Q&A exchanges
- Q3 FY2022Earnings2022-11-0916 Q&A exchanges
- Q2 FY2022Earnings2022-08-0934 Q&A exchanges
- Q1 FY2022Earnings2022-05-0418 Q&A exchanges
- Q4 FY2021Earnings2022-02-2420 Q&A exchanges
- Q3 FY2021Earnings2021-11-0317 Q&A exchanges
- Q2 FY2021Earnings2021-08-0419 Q&A exchanges
- Q1 FY2021Earnings2021-05-0529 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-04EPS— vs $-0.87—Rev— vs ——EODHD
- Q1 FY20262026-05-05EPS$-0.30 vs $-0.78+61.1%Rev$246.1M vs ——EODHD
- Q4 FY20252026-02-24EPS$-1.15 vs $-1.33+13.7%Rev$203.0M vs ——EODHD
- Q3 FY20252025-10-28EPS$-0.80 vs $-1.22+34.4%Rev$156.7M vs ——EODHD
- Q2 FY20252025-07-29EPS$0.70 vs $-0.24+100.0%Rev$452.0M vs ——EODHD
- Q1 FY20252025-05-04EPS$-0.92 vs $-1.01+8.5%Rev$131.6M vs ——EODHD
- Q4 FY20242025-02-18EPS$-0.43 vs $-0.84+49.0%Rev$226.6M vs ——EODHD
- Q3 FY20242024-11-05EPS$-0.95 vs $-1.16+18.1%Rev$133.8M vs ——EODHD
- Q2 FY20242024-07-31EPS$-0.45 vs $-0.92+51.1%Rev$225.3M vs ——EODHD
- Q1 FY20242024-05-06EPS$-0.98 vs $-1.05+6.7%Rev$119.5M vs ——EODHD
- Q4 FY20232024-02-20EPS$-0.06 vs $-0.83+92.8%Rev$119.5M vs ——EODHD
- Q3 FY20232023-11-01EPS$-1.03 vs $-1.04+1.0%Rev$144.2M vs ——EODHD
- Q2 FY20232023-08-08EPS$-0.60 vs $-0.90+33.3%Rev$188.4M vs ——EODHD
- Q1 FY20232023-05-02EPS$-0.87 vs $-0.91+4.4%Rev$130.5M vs ——EODHD
- Q4 FY20222023-02-21EPS$-1.36 vs $-0.92-47.8%Rev$151.9M vs ——EODHD
- Q3 FY20222022-11-08EPS$-0.33 vs $-0.74+55.4%Rev$159.8M vs ——EODHD
- Q2 FY20222022-08-08EPS$-0.74 vs $-0.62-19.4%Rev$133.8M vs ——EODHD
- Q1 FY20222022-05-03EPS$-0.46 vs $-0.71+35.2%Rev$141.9M vs ——EODHD
- Q4 FY20212022-02-23EPS$1.41 vs $0.28+100.0%Rev$440.0M vs ——EODHD
- Q3 FY20212021-11-02EPS$-0.58 vs $-0.53-9.4%Rev$133.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | — | $-0.87 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $-0.30 | $-0.78 | +61.1% | $246.1M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $-1.15 | $-1.33 | +13.7% | $203.0M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $-0.80 | $-1.22 | +34.4% | $156.7M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $0.70 | $-0.24 | +100.0% | $452.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $-0.92 | $-1.01 | +8.5% | $131.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-18 | $-0.43 | $-0.84 | +49.0% | $226.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.95 | $-1.16 | +18.1% | $133.8M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.45 | $-0.92 | +51.1% | $225.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.98 | $-1.05 | +6.7% | $119.5M | — | — | EODHD |
| Q4 FY2023 | 2024-02-20 | $-0.06 | $-0.83 | +92.8% | $119.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-1.03 | $-1.04 | +1.0% | $144.2M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.60 | $-0.90 | +33.3% | $188.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $-0.87 | $-0.91 | +4.4% | $130.5M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $-1.36 | $-0.92 | -47.8% | $151.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.33 | $-0.74 | +55.4% | $159.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.74 | $-0.62 | -19.4% | $133.8M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-0.46 | $-0.71 | +35.2% | $141.9M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $1.41 | $0.28 | +100.0% | $440.0M | — | — | EODHD |
| Q3 FY2021 | 2021-11-02 | $-0.58 | $-0.53 | -9.4% | $133.1M | — | — | EODHD |
Source: EODHD. IONS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks IONS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.01 | $2.52 | -20.4% | +1.6% | +4.1% |
| Q4 FY2026 | $1.91 | $2.32 | -17.6% | +2.6% | +4.2% |
| Q3 FY2026 | $2.00 | $2.38 | -15.8% | -3.9% | -6.1% |
| Q2 FY2026 | $2.07 | $2.60 | -20.4% | -4.2% | -5.3% |
| Q1 FY2025 | $2.12 | $2.44 | -13.3% | -1.5% | -0.6% |
| Q4 FY2025 | $2.31 | $2.55 | -9.5% | -2.4% | -2.3% |
| Q3 FY2025 | $2.19 | $2.65 | -17.4% | -6.9% | -9.0% |
| Q2 FY2025 | $2.07 | $2.59 | -20.1% | +0.7% | +3.3% |
| Q1 FY2024 | $2.27 | $2.50 | -9.0% | -4.6% | -2.1% |
| Q4 FY2024 | $2.27 | $2.68 | -15.4% | 0.0% | +1.0% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Brett P MoniaCEO5 mo21 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • guidance suspended Q1 FY2026
- Elizabeth L HougenCFO5 mo8 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last call held guidance Q2 FY2026
- Joseph BaroldiEVP, Chief Business Officer5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance raise Q3 FY2026
- Patrick R O'NeilEVP CLO & General Counsel5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q1 FY2026
- C Frank BennettEVP, Chief Scientific Officer5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • guidance suspended Q1 FY2026
- Kyle JenneEVP, Chf GL Pdt Str Ofcr3 mo9 callsCurrentSample
DIVISION_HEAD since 2026 • 2/2 beats (100%) • last call held guidance Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IONS.
$ curl https://api.spokenalpha.com/v1/companies/IONSFAQ
Frequently asked about IONS
Where can I find IONIS PHARMACEUTICALS INC's (IONS) earnings call transcripts?
Spoken Alpha indexes IONS's earnings call transcripts at https://spokenalpha.com/companies/IONS. Each call links to attributed speakers and parsed analyst Q&A. IONIS PHARMACEUTICALS INC's own investor relations page is at https://ir.ionis.com/.
When was IONIS PHARMACEUTICALS INC's most recent earnings call?
IONIS PHARMACEUTICALS INC (IONS) held its most recent earnings call on 2026-04-29, covering fiscal Q1 2026.
What sector is IONS in?
IONIS PHARMACEUTICALS INC (IONS) operates in the Healthcare sector (Biotechnology industry).